These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25200860)

  • 1. Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.
    Ali NA; Wu J; Hochgräfe F; Chan H; Nair R; Ye S; Zhang L; Lyons RJ; Pinese M; Lee HC; Armstrong N; Ormandy CJ; Clark SJ; Swarbrick A; Daly RJ
    Breast Cancer Res; 2014 Sep; 16(5):437. PubMed ID: 25200860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
    Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer.
    Andrechek ER; Muller WJ
    Breast Cancer Res; 2000; 2(3):211-6. PubMed ID: 11250712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the src or polyoma middle T oncogenes: cooperation between src and HGF/Met in invasion.
    Empereur S; Djelloul S; Di Gioia Y; Bruyneel E; Mareel M; Van Hengel J; Van Roy F; Comoglio P; Courtneidge S; Paraskeva C; Chastre E; Gespach C
    Br J Cancer; 1997; 75(2):241-50. PubMed ID: 9010033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
    Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN
    Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer.
    Organ SL; Tong J; Taylor P; St-Germain JR; Navab R; Moran MF; Tsao MS
    J Proteome Res; 2011 Jul; 10(7):3200-11. PubMed ID: 21609022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
    Zhang S; Chung WC; Miele L; Xu K
    Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SK4 channels modulate Ca
    Steudel FA; Mohr CJ; Stegen B; Nguyen HY; Barnert A; Steinle M; Beer-Hammer S; Koch P; Lo WY; Schroth W; Hoppe R; Brauch H; Ruth P; Huber SM; Lukowski R
    Mol Oncol; 2017 Sep; 11(9):1172-1188. PubMed ID: 28557306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
    Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
    J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.
    Taneja P; Maglic D; Kai F; Sugiyama T; Kendig RD; Frazier DP; Willingham MC; Inoue K
    Cancer Res; 2010 Nov; 70(22):9084-94. PubMed ID: 21062982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
    Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T
    J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
    Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
    Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
    Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproductive history determines Erbb2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model.
    Ordonez LD; Melchor L; Greenow KR; Kendrick H; Tornillo G; Bradford J; Giles P; Smalley MJ
    Dis Model Mech; 2021 May; 14(5):. PubMed ID: 34003256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.